Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Karyopharm Therapeutics Inc.
Trials need funding. See this company's dilution risk and cash position.
- Phase 3Completed
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
Selinexor, Bortezomib
Multiple Myeloma
NCT03110562Enrollment402StartMay 2017Primary CompletionFeb 2020CompletionMay 2022 - Phase 3Completed
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
Selinexor, Matching placebo for selinexor
Endometrial Cancer
NCT03555422Enrollment263StartJan 2018Primary CompletionJan 2022CompletionApr 2025 - Phase 3Active, not recruiting
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Selinexor, Selinexor
Myelofibrosis
NCT04562389Enrollment353StartMar 2021Primary CompletionFeb 2026CompletionMar 2028est. - Phase 3Active, not recruiting
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Selinexor, Matching Placebo for selinexor
Endometrial Cancer
NCT05611931Enrollment257StartApr 2023Primary CompletionMay 2026CompletionJan 2028est. - Phase 2/3Completed
Selinexor in Advanced Liposarcoma
Selinexor, Placebo
Dedifferentiated Liposarcoma
NCT02606461Enrollment342StartJan 2016Primary CompletionOct 2020CompletionOct 2021 - Phase 2/3Active, not recruiting
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Selinexor (combination therapy), Selinexor (combination therapy)
Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT04442022Enrollment501StartSep 2020Primary CompletionDec 2026est.CompletionDec 2026est. - Phase 2Terminated
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
Selinexor
Glioblastoma, Glioma
NCT01986348Enrollment76StartMar 2014Primary CompletionJan 2020CompletionJan 2020 - Phase 2Completed
Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies
Selinexor
Ovarian Carcinoma, Endometrial Carcinoma +1
NCT02025985Enrollment116StartApr 2014Primary CompletionJan 2017CompletionMar 2017 - Phase 2Completed
Selinexor (KPT-330) in Older Patients With Relapsed AML
Selinexor, Hydroxyurea
Acute Myeloid Leukemia (AML)
NCT02088541Enrollment317StartMar 2014Primary CompletionJan 2018CompletionJan 2018 - Phase 2Terminated
Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation
selinexor
Richter's Transformation
NCT02138786Enrollment27StartNov 2014Primary CompletionAug 2016CompletionAug 2016 - Phase 2Terminated
SHIP (Selinexor in Hormone Insensitive Prostate Cancer)
Selinexor
Prostate Cancer
NCT02146833Enrollment20StartMay 2014Primary CompletionApr 2016CompletionApr 2016 - Phase 2Terminated
Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
Selinexor (KPT-330)
Squamous Cell Carcinoma
NCT02213133Enrollment45StartSep 2014Primary CompletionDec 2015CompletionDec 2015 - Phase 2Active, not recruiting
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Selinexor, Selinexor
Diffuse Large B-cell Lymphoma
NCT02227251Enrollment244StartNov 2014Primary CompletionDec 2026est.CompletionDec 2026est. - Phase 2Terminated
Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
Selinexor
Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)
NCT02314247Enrollment16StartFeb 2015Primary CompletionJan 2016CompletionFeb 2016 - Phase 2Completed
Selinexor Treatment of Refractory Myeloma
Selinexor, Dexamethasone
Multiple Myeloma
NCT02336815Enrollment202StartMay 2015Primary CompletionJul 2019CompletionJul 2019 - Phase 2Withdrawn
Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients
Selinexor
Myelodysplastic Syndrome
NCT02431351Enrollment0StartNov 2015Primary CompletionDec 2017est.CompletionMay 2019est. - Phase 2Withdrawn
Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
Selinexor, Placebo (for selinexor)
Multiple Myeloma
NCT02628704Enrollment0StartDec 2015Primary CompletionJun 2017est.CompletionJun 2018est. - Phase 2Completed
Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection
Selinexor
Coronavirus Infection
NCT04349098Enrollment190StartApr 2020Primary CompletionOct 2020CompletionOct 2020 - Phase 2Withdrawn
Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19
Selinexor
Coronavirus Infection
NCT04355676Enrollment0StartApr 2020Primary CompletionAug 2020CompletionAug 2020 - Phase 2Recruiting
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Selinexor, Dexamethasone
Multiple Myeloma, Refractory
NCT04414475Enrollment127StartJul 2020Primary CompletionJan 2028est.CompletionJan 2028est. - Phase 2Active, not recruiting
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
Selinexor
Myelofibrosis
NCT04562870Enrollment112StartMar 2021Primary CompletionSep 2026est.CompletionSep 2026est. - Phase 2Terminated
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Selinexor, Pembrolizumab
Locally Advanced Unresectable or Metastatic Melanoma
NCT04768881Enrollment15StartMay 2021Primary CompletionSep 2023CompletionSep 2023 - Phase 2Terminated
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
Selinexor, Pembrolizumab
Metastatic Colorectal Cancer
NCT04854434Enrollment13StartJun 2021Primary CompletionJun 2022CompletionJun 2022 - Phase 2Recruiting
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Selinexor 60 mg, Selinexor 40 mg
Myelofibrosis, Moderate Thrombocytopenia +1
NCT05980806Enrollment58StartApr 2024Primary CompletionJun 2027est.CompletionOct 2028est. - Phase 1/2Recruiting
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Selinexor, Dexamethasone
Multiple Myeloma
NCT02343042Enrollment300StartOct 2015Primary CompletionApr 2027est.CompletionApr 2027est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 3 | Completed | Selinexor, Bortezomib | NCT03110562 |
| Phase 3 | Completed | Selinexor, Matching placebo for selinexor | NCT03555422 |
| Phase 3 | Active, not recruiting | Selinexor, Selinexor | NCT04562389 |
| Phase 3 | Active, not recruiting | Selinexor, Matching Placebo for selinexor | NCT05611931 |
| Phase 2/3 | Completed | Selinexor, Placebo | NCT02606461 |
| Phase 2/3 | Active, not recruiting | Selinexor (combination therapy), Selinexor (combination therapy) | NCT04442022 |
| Phase 2 | Terminated | Selinexor | NCT01986348 |
| Phase 2 | Completed | Selinexor | NCT02025985 |
| Phase 2 | Completed | Selinexor, Hydroxyurea | NCT02088541 |
| Phase 2 | Terminated | selinexor | NCT02138786 |
| Phase 2 | Terminated | Selinexor | NCT02146833 |
| Phase 2 | Terminated | Selinexor (KPT-330) | NCT02213133 |
| Phase 2 | Active, not recruiting | Selinexor, Selinexor | NCT02227251 |
| Phase 2 | Terminated | Selinexor | NCT02314247 |
| Phase 2 | Completed | Selinexor, Dexamethasone | NCT02336815 |
| Phase 2 | Withdrawn | Selinexor | NCT02431351 |
| Phase 2 | Withdrawn | Selinexor, Placebo (for selinexor) | NCT02628704 |
| Phase 2 | Completed | Selinexor | NCT04349098 |
| Phase 2 | Withdrawn | Selinexor | NCT04355676 |
| Phase 2 | Recruiting | Selinexor, Dexamethasone | NCT04414475 |
| Phase 2 | Active, not recruiting | Selinexor | NCT04562870 |
| Phase 2 | Terminated | Selinexor, Pembrolizumab | NCT04768881 |
| Phase 2 | Terminated | Selinexor, Pembrolizumab | NCT04854434 |
| Phase 2 | Recruiting | Selinexor 60 mg, Selinexor 40 mg | NCT05980806 |
| Phase 1/2 | Recruiting | Selinexor, Dexamethasone | NCT02343042 |
1-25 of 37 trials